Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. (Q36107363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jacek Jassem

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Wojciech Biernat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tomasz Mandat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Renata Duchnowska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Bożena Jarosz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Bogumiła Czartoryska-Arłukowicz

29 February 2020

object named as

Bogumiła Czartoryska-Arłukowicz

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Jodi M Weidler

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Jeff Sperinde

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Mojgan Haddad

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Ahmed Chenna

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Weidong Huang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

John Winslow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Agnes Paquet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Yolanda Lie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Barbara Radecka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Rafal Staszkiewicz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Małgorzata Chudzik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

13 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1241-1249

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

29 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Progress in the biological understanding and management of breast cancer-associated central nervous system metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Receptor conversion in distant breast cancer metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Central nervous system metastases in breast cancer patients administered trastuzumab

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

CNS metastases in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Immunohistochemical profiles of brain metastases from breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

HER2 in brain metastases: issues of concordance, survival, and treatment.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Central nervous system metastasis from breast carcinoma. Autopsy study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588754

Radiation recall dermatitis may represent the Koebner phenomenon

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOV012

Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status

21 January 2018

1 reference

12 December 2020

Chemotherapy and pattern of metastases in breast cancer patients

1 reference

12 December 2020

EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer

1 reference

12 December 2020

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay

1 reference

12 December 2020

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOV012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

25681308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681308%20AND%20SRC:MED&resulttype=core&format=json